NCT03511768 is a Phase 1, PHASE2 clinical trial of 18F-AlF-NOTA-octreotide in Neuroendocrine Neoplasm, sponsored by Xiangya Hospital of Central South University.

Who is sponsoring NCT03511768?

NCT03511768 is sponsored by Xiangya Hospital of Central South University.

What drugs are being tested in NCT03511768?

Interventions in NCT03511768: 18F-AlF-NOTA-octreotide, PET/CT.

What condition does NCT03511768 study?

NCT03511768 studies Neuroendocrine Neoplasm.

Is NCT03511768 still recruiting?

NCT03511768 is currently status unknown. Last updated 30 April 2018.

Last reviewed 2018-04-30 · How we verify

NCT03511768

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

Status unknown Phase 1, PHASE2 Last updated 30 April 2018

What this trial tests

Phase 1, PHASE2 trial testing 18F-AlF-NOTA-octreotide in Neuroendocrine Neoplasm in 65 participants. Status unknown.

Timeline

2 January 2018

Primary endpoint
30 December 2019

30 December 2020

Quick facts

Lead sponsor	Xiangya Hospital of Central South University
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	65
Start date	2 January 2018
Primary completion	30 December 2019
Estimated completion	30 December 2020
Sites	1 location across China

Drugs / interventions tested

18F-AlF-NOTA-octreotide — full drug profile →
PET/CT

Conditions studied

Neuroendocrine Neoplasm — all drugs for Neuroendocrine Neoplasm →

Sponsor

Xiangya Hospital of Central South University

Who can join

18 and older, any sex, with Neuroendocrine Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the clinical value of \[18F\]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ） positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Fu C, Yu L, Miao Y, Liu X, et al · · 2023 · cited 121× · PMID 36873165 · DOI 10.1016/j.apsb.2022.07.020
Somatostatin receptor PET ligands - the next generation for clinical practice.
Pauwels E, Cleeren F, Bormans G, Deroose CM. · · 2018 · cited 116× · PMID 30510849
Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy.
Eychenne R, Bouvry C, Bourgeois M, Loyer P, et al · · 2020 · cited 77× · PMID 32887456 · DOI 10.3390/molecules25174012
The Search for an Alternative to [<sup>68</sup>Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of <sup>18</sup>F-labeled Somatostatin Analog Development.
Waldmann CM, Stuparu AD, van Dam RM, Slavik R. · · 2019 · cited 40× · PMID 30867834 · DOI 10.7150/thno.31806

Verify or expand the search:

Other recruiting trials for Neuroendocrine Neoplasm

Currently open trials in the same condition.

NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
NCT06785597 — EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms · recruiting
NCT06732505 — A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens · Phase 1 · recruiting
NCT06855095 — Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial · Phase 2, PHASE3 · recruiting
NCT06276309 — Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors · recruiting

Other Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03511768 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
Last refreshed: 30 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03511768.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing